Tirzepatide and the mouth: a signal in 196,000 records, not yet a proof

Do the newest glucose-lowering drugs leave a trace in the mouth? This retrospective cohort study compared tirzepatide, a dual GIP/GLP-1 receptor agonist, with GLP-1 receptor agonists (GLP-1RAs) in adults with type 2 diabetes, looking at recorded oral and periodontal outcomes.

Data came from the TriNetX Global Collaborative Network, a large federated database of electronic health records. Adults with type 2 diabetes who started tirzepatide or a GLP-1RA between May 2022 and May 2025 were matched 1:1 by propensity score on baseline characteristics from the previous year. After matching, each group included 97,993 patients. Cox models estimated hazard ratios over one year of follow-up, with subgroup, extended follow-up, active-comparator, composite-outcome and E-value analyses as sensitivity checks.

Over one year, tirzepatide was associated with lower risks of several recorded outcomes: periodontitis (HR 0.70), peri-implant complications (HR 0.61), oral or maxillofacial infections (HR 0.70), tooth extraction (HR 0.89) and periodontal procedures (HR 0.89). Mortality was also lower (HR 0.69). The composite oral and periodontal outcome was lower with tirzepatide (HR 0.87), and the direction of the results held across the additional analyses.

The authors themselves are careful. These are diagnoses and procedures recorded in medical records, not systematic periodontal examinations: recorded event rates were low, and dental data in general health records are incomplete. The design is observational, so residual confounding (better metabolic control, weight loss, access to care, socioeconomic profile of patients who receive the newer drug) cannot be excluded. The lower mortality in the tirzepatide group is itself a reminder that the two groups may differ in ways matching did not capture. The associations need confirmation in prospective studies with proper dental assessment.

Clinical relevance: the link between glycaemic control and periodontal health is well established, and incretin-based drugs are now part of daily medicine. This study does not show that tirzepatide protects the periodontium. It suggests a signal worth testing, and a practical point: the medication list of the diabetic patient is becoming more relevant to the periodontist and implantologist, and collaboration with the diabetologist more natural.